Skip to content

The effect of high concentration of hydrogen inhalation on non-alcoholic fatty liver disease in community

The effect of high concentration of hydrogen inhalation on non-alcoholic fatty liver disease in community

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-16009114
Enrollment
Unknown
Registered
2016-08-29
Start date
2016-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease

Interventions

treatment group:aerosol inhalation with hydrogen and oxygen
control group:aerosol inhalation with nitrogen and oxygen

Sponsors

Taishan Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. aged 30-70 years old; 2. NAFLD patients meet the diagnosis criteria according to: The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association); 3. The patients agreed to participate in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1) fatty liver caused by a specific cause, such as tamoxifen; 2) combined with other causes of liver disease such as viral hepatitis (such as HBsAg or anti HCV positive), liver cirrhosis, drug-induced liver injury, autoimmune diseases, metabolic liver disease, etc; 3) Alcohol abuse, alcohol consumption >70g/week for female patient or >140g/week for male patient; 4) Patient who is receiving insulin treatment; 5) patients with severe disease of other system, mental disease, or senile dementia patients, epilepsy patients; hypothyroidism or Cushing's syndrome; 6) Have received Levocarnitine treatment within 30 days; Hypersensitive to Levocarnitine and its derivatives; 7) Patient has participated in other drug clinical trial within 30 days; 8) use of drugs such as calcium channel blockers, high dose of synthetic estrogens, methotrexate, amiodarone steroids, chloroquine; 9) Pregnant or lactating female, or female of childbearing potential does not use adequate contraceptive methods; 10) other situations that researchers think the patient is not suitable for the research.

Design outcomes

Primary

MeasureTime frame
ALT level;AST level;L/S ratio;

Secondary

MeasureTime frame
TG;TC;BMI;abdomen circumference;Fasting blood glucose;HDL-C;LDL-c;

Countries

China

Contacts

Public ContactQin Shucun

Taishan Medical University

shucunqin@hotmail.com+86 0538 6222986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026